Agrawal Dhiraj, Gupta Deepak, Nathani Rohit, Dhore Prashant, Meshram Megha, Bhatia Shobna J, Shukla Akash
Department of Gastroenterology, Seth GSMC and KEM Hospital, Mumbai 400 012, India.
J Clin Exp Hepatol. 2022 May-Jun;12(3):861-870. doi: 10.1016/j.jceh.2021.10.148. Epub 2021 Nov 3.
There is lack of data on long-term outcomes of patients with Budd-Chairi Syndrome (BCS) treated with medical therapy including anticoagulation alone.
Consecutive patients (N = 138, mean [standard deviation, SD] age 29.3 [12.9] years; 66 men) with BCS, treated with medical therapy alone including anticoagulation, with minimum follow-up of 12 months were included. Initial response was classified as complete (CR), partial (PR) or nonresponse (NR) and on follow-up as loss of response (LoR) or maintenance of response (MoR). The association of baseline, clinical and biochemical parameters with different responses was evaluated.
Seventy-six patients (55.1%) had CR, 26 (18.8%) had PR and 36 (26.1%) had NR. None with PR or NR had CR later. At a median follow-up of 40 (range 12-174) months, LoR was more common in PR group than in CR group (12 [46.2%] vs 18 [23.7%], = 0.03). LoR was associated with presence of ascites (odds ratio [OR] 1.5; 95% confidence interval [CI] 0.06-0.71), gastrointestinal bleed (OR 1.33; 95% CI 0.09-0.82) or jaundice (OR 1.01; 95% CI 0.11-0.97) at baseline and duration of follow-up (OR 0.018; 95% CI 1.006-1.030). Mortality was higher in NR (28 [77.8%]) compared with CR (15 [19.7%], = 0.001) and PR (8 [30.8%], = 0.001). On binary logistic regression analysis, presence of ascites at baseline was associated with LoR (OR 0.303 [0.098-0.931]).
Patients with initial CR have better survival than nonresponders. One-third had LoR on follow-up. The presence of ascites at baseline is associated with LoR.
关于布加综合征(BCS)患者单纯接受包括抗凝治疗在内的药物治疗的长期预后数据匮乏。
纳入连续的138例BCS患者(平均[标准差,SD]年龄29.3[12.9]岁;66例男性),这些患者仅接受包括抗凝治疗在内的药物治疗,且随访时间至少为12个月。初始反应分为完全缓解(CR)、部分缓解(PR)或无反应(NR),随访时分为反应丧失(LoR)或反应维持(MoR)。评估基线、临床和生化参数与不同反应之间的关联。
76例患者(55.1%)达到CR,26例(18.8%)达到PR,36例(26.1%)为NR。PR或NR患者均未随后达到CR。在中位随访40(范围12 - 174)个月时,PR组LoR比CR组更常见(12例[46.2%]对18例[23.7%],P = 0.03)。LoR与基线时存在腹水(比值比[OR]1.5;95%置信区间[CI]0.06 - 0.71)、胃肠道出血(OR 1.33;95%CI 0.09 - 0.82)或黄疸(OR 1.01;95%CI 0.11 - 0.97)以及随访持续时间(OR 0.018;95%CI 1.006 - 1.030)相关。NR组死亡率(28例[77.8%])高于CR组(15例[19.7%],P = 0.001)和PR组(8例[30.8%],P = 0.001)。二元逻辑回归分析显示,基线时存在腹水与LoR相关(OR 0.303[0.098 - 0.931])。
初始达到CR患者的生存率高于无反应者。三分之一患者在随访时出现LoR。基线时存在腹水与LoR相关。